CD274 and neoplasm: However, unlike other malignancies such as non-small cell lung cancer and melanoma, where the use of ICIs can be guided by PD-L1 tumor expression or tumor mutational burden, there are currently no validated biomarkers to predict response in patients with mRCC receiving ICIs [79,80,81,82].